COLTENE Holding Valuation

Q: What is the Fair Price of CLHL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CLHL.F ($61.16) is trading below our estimate of [[fair value]] ($85.77)

Is CLHL.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLHL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLHL.F ($61.16) is trading below our estimate of fair value ($85.77)

Significantly Below Fair Value: CLHL.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLHL.F?

Key metric: As CLHL.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CLHL.F. This is calculated by dividing CLHL.F's market cap by their current earnings.
What is CLHL.F's PE Ratio?
PE Ratio	25.5x
Earnings	CHF 11.95m
Market Cap	CHF 304.75m

CLHL.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	13.2x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does CLHL.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CLHL.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.5x
OSUR OraSure Technologies	26.1x	-46.8%	US$291.7m
UTMD Utah Medical Products	14x	n/a	US$213.4m
AVNS Avanos Medical	35.3x	n/a	US$775.6m
EMBC Embecta	14.8x	27.0%	US$1.1b
CLHL.F COLTENE Holding	25.5x	20.9%	US$304.8m

Price-To-Earnings vs Peers: CLHL.F is expensive based on its Price-To-Earnings Ratio (25.5x) compared to the peer average (21.1x).

Price to Earnings Ratio vs Industry

How does CLHL.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 Companies	Price / Earnings	Estimated Growth	Market Cap
BDMD Baird Medical Investment Holdings	4.5x	n/a	US$55.46m
MHUA Meihua International Medical Technologies	1.4x	n/a	US$13.07m
PAVM PAVmed	0.5x	-90.0%	US$8.40m
RTSL Rapid Therapeutic Science Laboratories	0.3x	n/a	US$18.99k

No more companies available in this PE range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: CLHL.F is good value based on its Price-To-Earnings Ratio (25.5x) compared to the US Medical Equipment industry average (37.5x).

Price to Earnings Ratio vs Fair Ratio

What is CLHL.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLHL.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	25.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CLHL.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.